Abstracts Archive - Page 1506 of 2607 - ACR Meeting Abstracts

Abstract Number: 1781 • 2017 ACR/ARHP Annual Meeting
Pituitary Disease and Granulomatosis with Polyangiitis: A Collaborative Canadian Case Series and Review of the Literature
Martha Decker¹, Christian Pagnoux², Constance Chik³, Nader A. Khalidi⁴, Derek Emery⁵ and Elaine Yacyshyn⁶, ¹Division of Rheumatology, University of Alberta, Edmonton, AB, Canada, ²Division of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ³Division of Endocrinology, University of Alberta, Edmonton, AB, Canada, ⁴Rheumatology, McMaster University, Hamilton, ON, Canada, ⁵Division of Radiology, University of Alberta, Edmonton, AB, Canada, ⁶Medicine, University of Alberta, Edmonton, AB, Canada
Background/Purpose: Pituitary involvement in granulomatosis with polyangiitis (GPA) is rare with an incidence of approximately 1%. Objectives were: (1) Describe ten new cases of pituitary…
Abstract Number: 1782 • 2017 ACR/ARHP Annual Meeting
Mycophenolic Acid Decreases IL-10 and IL-6 Production By B Cells of Granulomatosis with Polyangiitis Patients and Healthy Controls in Vitro
Anouk von Borstel¹, Wayel H. Abdulahad², Abraham Rutgers², Judith Land², Coen A. Stegeman¹, Peter Heeringa³ and Jan-Stephan F. Sanders¹, ¹Internal Medicine, Division of Nephrology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ²Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ³Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands
Background/Purpose: Granulomatosis with polyangiitis (GPA) is a relapsing autoimmune disease affecting small- to medium-sized blood vessels. B cells are thought to play an important antibody-independent…
Abstract Number: 1783 • 2017 ACR/ARHP Annual Meeting
The Value of a Combination of Serum Proteins to Identify Response to Induction Therapy Among Patients with ANCA-Associated Vasculitis
Sadao Jinno^1,2, S. Reza Jafarzadeh³, Roscoe Warner⁴, Ulrich Specks⁵, John H. Stone⁶, Gary S. Hoffman⁷, Cees G.M. Kallenberg⁸, Carol A. Langford⁹, Philip Seo¹⁰, Robert F. Spiera¹¹, E. William St Clair¹², Kent Johnson¹³, Peter A. Merkel¹⁴ and Paul A. Monach², ¹Rheumatology, Boston University School of Medicine, Boston, MA, ²Boston University School of Medicine, Boston, MA, ³Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, MA, ⁴University of Michigan Medical School, Ann Arbor,, MI, ⁵Mayo Clinic College of Medicine, Rochester, MN, ⁶Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ⁷Rheumatology, Cleveland Clinic, Cleveland, OH, ⁸Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ⁹Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, ¹⁰Medicine, Johns Hopkins University, Baltimore, MD, ¹¹Rheumatology, Hospital for Special Surgery, New York, NY, ¹²Rheumatology, Duke University Medical Center, Durham, NC, ¹³University of Michigan Medical School, Ann Arbor, MI, ¹⁴Division of Rheumatology, University of Pennsylvania; Perelman School of Medicine, Philadelphia, PA
Background/Purpose: Most patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) achieve clinical remission after induction therapy. However, even among patients who achieve remission, induction therapy…
Abstract Number: 1784 • 2017 ACR/ARHP Annual Meeting
The Novel Anti-CD40 Monoclonal Antibody CFZ533 Shows Beneficial Effects in Patients with Primary Sjögren’s Syndrome: A Phase IIa Double-Blind, Placebo-Controlled Randomized Trial
Benjamin Fisher¹, Margit Zeher², Wan-Fai Ng³, Michele Bombardieri⁴, Maximilian Posch⁵, Athena S Papas⁶, Arwa M Farag⁶, Thomas Daikeler⁷, Bettina Bannert⁸, Alan J. Kivitz⁹, Steven E. Carsons¹⁰, David A. Isenberg¹¹, Francesca Barone¹², Simon Bowman¹³, Pascal Espie¹⁴, Grazyna Wieczorek¹⁴, Pierre Moulin¹⁴, David Floch¹⁴, Cyrielle Dupuy¹⁴, Xiaohui Ren¹⁴, Petra Faerber¹⁴, Andrew M Wright¹⁵, Hans Ulrich Hockey¹⁵, Michael Rotte¹⁴, James S. Rush¹⁵ and Peter Gergely¹⁴, ¹Rheumatology Research Group, University of Birmingham, Birmingham, United Kingdom, ²Division of Clinical Immunology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary., Debrecen, Hungary, ³Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom, ⁴Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Queen Mary University of London, UK, London, United Kingdom, ⁵Charité Research Organisation GmbH, Berlin, Germany, ⁶Tufts University, Boston, MA, ⁷Rheumatology, University Hospital Basel, Basel, Switzerland, ⁸University Hospital Basel, Basel, Switzerland, ⁹Department of Rheumatology, Altoona Center for Clinical Research, Duncansville, PA, ¹⁰NYU Winthrop University Hospital, Department of Medicine, Mineola, NY, ¹¹Centre for Rheumatology, Division of Medicine, University College London, London, United Kingdom, ¹²Institute of Inflammation and Ageing (IIA), University of Birmingham, Birmingham, United Kingdom, ¹³Department of Rheumatology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK, Birmingham, United Kingdom, ¹⁴Novartis Institutes for Biomedical Research, Basel, Switzerland, ¹⁵Novartis Pharmaceuticals Corporation, Basel, Switzerland
Background/Purpose: Primary Sjogren’s syndrome (pSS) is a systemic, progressive autoimmune disease characterized by formation of ectopic germinal centers in exocrine glands and secretory gland dysfunction.…
Abstract Number: 1785 • 2017 ACR/ARHP Annual Meeting
Serious or Opportunistic Infections in Infants Born to Pregnant Women with Rheumatoid Arthritis and Treated with a Biologic Medication
Christina D Chambers¹, Diana L Johnson², Yunjun Luo³, Ronghui Xu⁴ and Kenneth L Jones³, ¹Pediatrics and Family Medicine and Public Health, University of California San Diego, La Jolla, CA, ²Department of Pediatrics, University of California, San Diego, La Jolla, CA, ³Pediatrics, University of California San Diego, La Jolla, CA, ⁴Department of Family Medicine and Public Health, University of California, San Diego, La Jolla, CA
Background/Purpose: Use of biologic therapies for rheumatoid arthritis (RA) in pregnancy is common. There is theoretical concern that these medications could interfere with postnatal…
Abstract Number: 1786 • 2017 ACR/ARHP Annual Meeting
Lupus Nephritis Is Linked to Immunity to an Intestinal Commensal Lachnospiracaea Species
Gregg J. Silverman¹, Doua F. Azzouz², Hanane El Bannoudi², Aidana Omarbekova³, Brad H. Rovin⁴, Roberto Caricchio⁵, Alexander Alekseyenko⁶ and Jill P. Buyon², ¹Department of Medicine, New York University School of Medicine, New York, NY, ²Medicine, New York University School of Medicine, New York, NY, ³New York University School of Medicine, New York, NY, ⁴Ohio State University Medical Center, Columbus, OH, ⁵Medicine/Rheumatology, Temple University, Philadelphia, PA, ⁶Medical University of South Carolina, Charleston, SC
Background/Purpose: A transmissible agent has long been suspected in the pathogenesis of SLE, yet the potential contribution of members of the intestinal microbiome to the…
Abstract Number: 1787 • 2017 ACR/ARHP Annual Meeting
Efficacy and Safety of Continuing Versus Withdrawing Adalimumab in Maintaining Remission in Patients with Non-Radiographic Axial Spondyloarthritis
Robert B.M. Landewé¹, Joachim Sieper², Philip J Mease³, Robert D Inman⁴, Xin Wang⁵, Mei Li⁵, Aileen L. Pangan⁵ and Jaclyn K. Anderson⁵, ¹University of Amsterdam, Amsterdam, Netherlands, ²Charité Universitätsmedizin Berlin, Berlin, Germany, ³Swedish Medical Center and University of Washington, Seattle, WA, ⁴Department of Immunology, University of Toronto, Toronto, ON, Canada, ⁵AbbVie Inc., North Chicago, IL
Background/Purpose: It is not known whether TNF blockers can be stopped in non-radiographic (nr-axSpA) patients who are in remission. In ABILITY-1, adalimumab (ADA) significantly improved…
Abstract Number: 1788 • 2017 ACR/ARHP Annual Meeting
Dose Intra-Articular Injection of Corticosteroids Increase the Risk of Knee Osteoarthritis Progression? Data from the Osteoarthritis Initiative
Guang-hua Lei¹, Chao Zeng¹, Jie Wei^2,3, Yi-lun Wang¹ and Dong-xing Xie¹, ¹Department of orthopaedics, Xiangya Hospital, Central South University, Changsha, China, ²Health Management Center, Xiangya Hospital, Central South University, Changsha, China, ³Department of Epidemiology and Health Statistics, Xiangya School of Public Health, Central South University, Changsha, China
Background/Purpose: Although intra-articular injection of corticosteroids (IAIC) has been one of the modalities of treatment for symptomatic knee OA, the recommendations for its use are…
Abstract Number: 1789 • 2017 ACR/ARHP Annual Meeting
Improved Survival with Transplantation in Granulomatosis with Polyangiitis in the United States: Data from the US Renal Data System
Zachary S. Wallace¹, Rachel Wallwork², Leo Lu³, John H. Stone⁴, Yuqing Zhang⁵ and Hyon K. Choi⁶, ¹Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²Department of Medicine, Massachusetts General Hospital, Boston, MA, ³Allergy, Immunology, and Rheumatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁴Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ⁵Department of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁶Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA
Improved Survival with Transplantation in Granulomatosis with Polyangiitis in the United States: Data from the US Renal Data SystemBackground/Purpose: Granulomatosis with polyangiitis (GPA) is a…
Abstract Number: 1790 • 2017 ACR/ARHP Annual Meeting
Sphingosine -1 Phosphate Receptor-1-Mediated Endothelial Cell Barrier Function Protects Against Immune Complex-Induced Vascular Injury: A Potential Novel Therapeutic Target for SLE
Nathalie Burg¹, Steven Swendeman², Stefan Worgall³, Timothy Hla² and Jane E. Salmon¹, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Boston Children's Hospital, Boston, MA, ³Pediatrics/ Pulmonary, Weill Cornell Medical Center, New York, NY
Background/Purpose: Sphingosine 1-phosphate (S1P), a bioactive lysophospholipid, is important for vascular homeostasis via signaling through S1P receptors. HDL-bound apolipoprotein M (ApoM) is a physiological S1P…
Abstract Number: 1791 • 2017 ACR/ARHP Annual Meeting
TET1 Is an Important Transcriptional Activator of the Tnfa Locus in Macrophages
Emmanuel Karouzakis¹, Fangfang Sun², Agnieszka Pajak¹, Shuang Ye², Steffen Gay¹, Oliver Distler³ and Michel Neidhart¹, ¹Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ²Department of Rheumatology, Renji Hospital South Campus, School of Medicine, Shanghai Jiao Tong University, Shanghai, China, ³Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland
Background/Purpose: Activated macrophages are found in the inflamed and hyperplastic synovial RA tissue. Macrophages are the main producers of high levels of pro-inflammatory cytokines such…
Abstract Number: 1792 • 2017 ACR/ARHP Annual Meeting
Distinct and Overlapping Activities of IL-17A and TNF on the Expression of Proinflammatory Cytokines and MMPs in Psoriatic Arthritis: Rationale for Anti-IL-17A/Anti-Tnfalpha Combination Therapy?
Xiaofei Xu¹, Nadine Davelaar², Anne-Marie Otten-Mus³, Patrick Asmawidjaja², J.M.W. Hazes⁴, Dominique Baeten⁵, Marijn Vis⁶, Radjesh Bisoendial¹ and Erik Lubberts², ¹Rheumatology, Erasmus MC, Rotterdam, Netherlands, ²Rheumatology and Immunology, Erasmus MC, University Medical Center, Rotterdam, Netherlands, ³Immunology, Erasmus MC, University Medical Center, Rotterdam, Netherlands, ⁴Department of Rheumatology, Erasmus University Medical Centre, Rotterdam, Netherlands, ⁵Clinical Immunology and Rheumatology/Experimental immunology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ⁶Rheumatology, Erasmus Medical Centre, Rotterdam, Netherlands
Background/Purpose: TNF and IL-17A are proinflammatory cytokines critically involved in the pathogenesis of psoriatic arthritis (PsA). Currently, targeting TNF is the first choice of a…
Abstract Number: 1793 • 2017 ACR/ARHP Annual Meeting
Interleukin-17 Is Not a Determinant for the Pro- or Anti-Inflammatory Character of Interleukin-22 in Experimental Arthritis
Debbie M. Roeleveld¹, Loreto Parga Vidal², Monique M. Helsen², Birgitte Walgreen³, Bianka Marklein⁴, Karl Skriner⁵, Martin Hegen⁶, Peter L. van Lent², Fons A.J. van de Loo², Wim B. van den Berg², Peter M. van der Kraan² and Marije I. Koenders², ¹Experimental Rheumatology, Radboud University Medical Center, Nijmegen, Netherlands, ²Experimental Rheumatology, Radboud university medical center, Nijmegen, Netherlands, ³Experimental, Radboud university medical center, Nijmegen, Netherlands, ⁴Humboldt University and Free University, Berlin, Germany, ⁵Department of Rheumatology and Clinical Immunology, Charité - University Medicine Berlin, Free University and Humboldt University Berlin, Berlin, Germany, ⁶Inflammation and Immunology Research Unit, Pfizer, Cambridge, MA
Background/Purpose: High interleukin-22 (IL-22) levels are detected in serum and synovial fluid of rheumatoid arthritis (RA) patients and have been shown to positively correlate with…
Abstract Number: 1794 • 2017 ACR/ARHP Annual Meeting
Overexpression of Interleuk-22 Induces Expression of the Negative Immune-Regulator SOCS3 and Potently Reduces Collagen-Induced Arthritis in Mice
Debbie M. Roeleveld¹, Monique M. Helsen², Birgitte Walgreen³, Elly Vitters², Fons A.J. van de Loo², Peter L. van Lent², Wim B. van den Berg², Peter M. van der Kraan² and Marije I. Koenders², ¹Experimental Rheumatology, Radboud University Medical Center, Nijmegen, Netherlands, ²Experimental Rheumatology, Radboud university medical center, Nijmegen, Netherlands, ³Experimental, Radboud university medical center, Nijmegen, Netherlands
Background/Purpose: High interleukin-22 (IL-22) levels are detected in serum and synovial fluid of rheumatoid arthritis (RA) patients and have been shown to positively correlate with…
Abstract Number: 1795 • 2017 ACR/ARHP Annual Meeting
IL-7 in Primary Sjogren Syndrome (pSS) Is Secreted By Salivary Gland Epithelial Cells after IFN Stimulation and Is Associated with B-Cell Activation
Alexandre Virone¹, Juliette Pascaud², Elodie Rivière¹, Jacques-Eric Gottenberg³, Véronique Le Guern⁴, Xavier Mariette¹ and Gaetane Nocturne⁵, ¹Université Paris Sud, Paris, France, ²U1184 IMVA, Université Paris Sud, Le Kremlin-Bicêtre Cedex, France, ³CNRS, Immunopathologie et Chimie Thérapeutique/Laboratory of Excellence Medalis, Institut de Biologie Moléculaire et Cellulaire, Strasbourg, France, ⁴Internal Medicine Department, Cochin Hospital, “René-Descartes Paris V” University, Paris, France, ⁵INSERM U1184, IMVA, Paris Sud University,LabEx LERMIT, Le Kremlin Bicêtre, France
Background/Purpose : pSS is characterized by a strong IFN signature, ectopic germinal centers formation and a chronic blood lymphopenia. IL-7 plays a central part in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].